CYP2D6 has numerous endogenous substrates including tamoxifen, a selective estrogen receptor modulator (SERM) commonly used to treat estrogen receptor-positive (ER+) breast cancer [7,8,9,10,11]. Here, CYP2D6 is linked to breast carcinoma.